Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroForte 5 versus Testogel 1% bioequivalence in men with hypogonadism
ACTRN12610000834055Phase 2Completed
- Sponsor
- Lawley Pharmaceuticals
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AndroForte and testosterone in Hypoandrogenism (TD) and androgen deficiency (2 arms), sponsored by Lawley Pharmaceuticals. Primary endpoint: Pharmacokinetic comparison of AndroForte 5 and Testogel 1%. Started Dec 2010; status: completed.
02
Drugs
AndroFortetestosterone
03
Conditions
Hypoandrogenism (TD)androgen deficiency
Beyond the preview
Go deeper on ACTRN12610000834055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000834055.